4.6 Article

Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer

Journal

PLOS ONE
Volume 10, Issue 10, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0140437

Keywords

-

Ask authors/readers for more resources

Introduction This study investigated the clinical characteristics and predictive factors for developing acute extended radiation pneumonitis with a focus on the presence and radiological characteristics of preexisting interstitial lung disease. Methods Of 1429 irradiations for lung cancer from May 2006 to August 2013, we reviewed 651 irradiations involving the lung field. The presence, compatibility with usual interstitial pneumonia, and occupying area of preexisting interstitial lung disease were retrospectively evaluated by pretreatment computed tomography. Cases of non-infectious, non-cardiogenic, acute respiratory failure with an extended bilateral shadow developing within 30 days after the last irradiation were defined as acute extended radiation pneumonitis. Results Nine (1.4%) patients developed acute extended radiation pneumonitis a mean of 6.7 days after the last irradiation. Although preexisting interstitial lung disease was found in 13% of patients (84 patients), 78% of patients (7 patients) with acute extended radiation pneumonitis cases had preexisting interstitial lung disease, which resulted in incidences of acute extended radiation pneumonitis of 0.35 and 8.3% in patients without and with preexisting interstitial lung disease, respectively. Multivariate logistic analysis indicated that the presence of preexisting interstitial lung disease (odds ratio = 22.6; 95% confidence interval = 5.29-155; p < 0.001) and performance status (>= 2; odds ratio = 4.22; 95% confidence interval = 1.06-20.8; p = 0.049) were significant predictive factors. Further analysis of the 84 patients with preexisting interstitial lung disease revealed that involvement of more than 10% of the lung field was the only independent predictive factor associated with the risk of acute extended radiation pneumonitis (odds ratio = 6.14; 95% confidence interval = 1.0-37.4); p = 0.038). Conclusions Pretreatment computed tomography evaluations of the presence of and area size occupied by preexisting interstitial lung disease should be assessed for safer irradiation of areas involving the lung field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer

Kazuhisa Nakashima, Hiroaki Akamatsu, Haruyasu Murakami, Takashi Niwa, Yasuo Iwamoto, Yuichi Ozawa, Toshihide Yokoyama, Hiroyasu Shoda, Nobuyuki Yamamoto, Hiroshige Yoshioka, Ken Masuda, Tateaki Naito, Keita Mori, Toshiaki Takahashi

ANTICANCER RESEARCH (2019)

Article Oncology

Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer

Yuichi Ozawa, Yusuke Amano, Kei Kanata, Hirotsugu Hasegwa, Takashi Matsui, Takuya Kakutani, Takafumi Koyauchi, Masayuki Tanahashi, Hiroshi Niwa, Koshi Yokomura, Takafumi Suda

MEDICAL ONCOLOGY (2019)

Article Oncology

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer

Hiroaki Akamatsu, Eriko Murakami, Jun Oyanagi, Ryota Shibaki, Takahiro Kaki, Eri Takase, Masanori Tanaka, Yuhei Harutani, Nao Yamagata, Yuka Okuda, Katsuyuki Furuta, Takeya Sugimoto, Shunsuke Teraoka, Atsushi Hayata, Nahomi Tokudome, Yuichi Ozawa, Keita Mori, Yasuhiro Koh, Nobuyuki Yamamoto

ONCOLOGIST (2020)

Article Oncology

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu, Katsuya Endo, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto

CANCER MEDICINE (2020)

Article Oncology

Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial

Kazuhisa Nakashima, Yuichi Ozawa, Haruko Daga, Hisao Imai, Motohiro Tamiya, Takaaki Tokito, Takahisa Kawamura, Hiroaki Akamatsu, Yuko Tsuboguchi, Toshiaki Takahashi, Nobuyuki Yamamoto, Keita Mori, Haruyasu Murakami

INVESTIGATIONAL NEW DRUGS (2020)

Article Medicine, General & Internal

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer

Yuichi Ozawa, Takeya Sugimoto, Yuichiro Azuma, Yuhei Harutani, Takanori Yoshikawa, Nobuyuki Yamamoto, Kuninobu Kanai

BMJ OPEN (2020)

Article Oncology

Importance of doctor-initiated management of the balance between work and treatment for lung cancer patients: Results of a nationwide survey by the Japan Lung Cancer Society

Satoshi Ikeda, Yuichi Ozawa, Ken Harada, Kazuo Hasegawa, Naomi Shimizu, Takako Seki, Yoshinori Hasegawa, Tetsuya Mitsudomi

CANCER MEDICINE (2020)

Article Oncology

CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50

Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi, Hiroaki Akamatsu, Eriko Murakami, Ryota Shibaki, Atsushi Hayata, Takeya Sugimoto, Masanori Tanaka, Toshiaki Takakura, Katsuyuki Furuta, Yuka Okuda, Kouichi Sato, Shunsuke Teraoka, Hiroki Ueda, Nahomi Tokudome, Yuka Kitamura, Junya Fukuoka, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto

Summary: CD24 positivity is negatively associated with progression-free survival (PFS) of ICI in patients with PD-L1 TPS < 50, and is related to a significant increase in CCL2. High CD47 TPS suppresses the increase in VEGF-A, D, and PDGF-AB/BB after ICI initiation.

CANCER SCIENCE (2021)

Article Nutrition & Dietetics

The effect of 1-hydroxy-vitamin D treatment in hospitalized patients with COVID-19: A retrospective study

Takashi Ogasawara, Yasuhisa Tajima, Naoto Nakamura, Hiroki Kanasaki, Wataru Matsuyama, Mitsuru Niwa, Yuichi Ozawa, Masayuki Sugiura, Masahito Ogiku, Jun Sato

Summary: This study aimed to evaluate the efficacy of 1-hydroxy-vitamin D in COVID-19 patients. The results showed that patients treated with 1-hydroxy-vitamin D had a significantly lower proportion of needing respiratory support and in-hospital mortality compared to the control group.

CLINICAL NUTRITION (2023)

Meeting Abstract Oncology

Longitudinal evaluation of PD-L1 expression on circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab

Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Nahomi Tokudome, Atsushi Hayata, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu, Katsuya Endo, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto

CLINICAL CANCER RESEARCH (2020)

Meeting Abstract Oncology

Clinical significance of vimentin-positive AXL-expressing circulating tumor cells in advanced non-small-cell lung cancer patients

Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu, Katsuya Endo, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto

MOLECULAR CANCER THERAPEUTICS (2019)

Meeting Abstract Oncology

Detection of serum protein levels for predicting clinical benefit in advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors

Jun Oyanagi, Yasuhiro Koh, Hiroaki Akamatsu, Koichi Sato, Shunsuke Teraoka, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Yuichi Ozawa, Keiichiro Akamatsu, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto

MOLECULAR CANCER THERAPEUTICS (2019)

Meeting Abstract Oncology

High-purity isolation method of rare cells for molecular analyses using microfluidic chip type cell sorter

Yasuhiro Koh, Mio Ikeda, Shunsuke Teraoka, Masayuki Ishige, Yuu Fujimura, Kazuo Takeda, Nahomi Tokudome, Yuichi Ozawa, Hiroki Ueda, Nobuyuki Yamamoto

CANCER RESEARCH (2019)

Meeting Abstract Oncology

Predictive significance of serum protein levels in advanced non-small cell lung cancer patients treated with pembrolizumab

Jun Oyanagi, Yasuhiro Koh, Shunsuke Teraoka, Kuninobu Kanai, Atsuhsi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto

CANCER RESEARCH (2019)

Meeting Abstract Oncology

Detection of AXL-expressing circulating tumor cells (CTCs) in non-small-cell lung cancer (NSCLC) patients using an automated microcavity array (MCA) system

Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Jun Oyanagi, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto

CANCER RESEARCH (2019)

No Data Available